Navigation Links
PAREXEL Reports Third Quarter Fiscal Year 2008 Financial Results
Date:4/23/2008

- Consolidated service revenue of $245.3 million grows 28% year-over-year

- Diluted earnings per share in the quarter were $0.25 - Backlog increases approximately 37% year-over-year to $1.9 billion; net

quarterly book-to-burn ratio equates to 1.52

BOSTON, April 23 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL) today announced its financial results for the third quarter and nine months ended March 31, 2008. The past and current period results reflect a two-for-one stock split which occurred on March 3, 2008.

For the three months ended March 31, 2008, PAREXEL's consolidated service revenue increased 28.3% to a record $245.3 million, compared with $191.2 million in the prior year period. The Company reported operating income of $22.7 million, or 9.3% of consolidated service revenue, in the third quarter of Fiscal Year 2008, versus operating income of $15.5 million, or 8.1% of consolidated service revenue, in the comparable quarter of the prior year. This represented a year-over-year increase of 46.8%. Included in these results was a favorable pre-tax restructuring benefit of $860,000 in the third quarter of Fiscal Year 2008, as noted in the financial charts contained within this press release. Net income for the quarter totaled $14.2 million, or $0.25 per diluted share, compared with net income of $10.8 million, or $0.19 per diluted share for the quarter ended March 31, 2007, an increase of 31.6%.

On a segment basis, consolidated service revenue for the third quarter of Fiscal Year 2008 consisted of $191.5 million in Clinical Research Services (CRS), $33.5 million in PAREXEL Consulting and Medical Communications (PCMS), and $20.3 million in Perceptive Informatics,
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
2. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
3. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
4. PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors
5. PAREXEL Announces Date of First Quarter Fiscal Year 2008 Earnings Release and Conference Call
6. PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results
7. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
8. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
9. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
10. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
11. PAREXEL International Announces 2-For-1 Stock Split

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...yendpointhasbeenmetforpatientswithadvanced-stage,o....24/PRNewswire-FirstCall/-AEternaZentarisInc.(NASD...euticalcompanyfocusedonendocrinetherapyandoncology...ywithitstargetedcytotoxicpeptideconjugate,AEZS-108...endometrialcancer.Inapersonalizedhealthcareapproac...
(Date:11/24/2009)...r24/PRNewswire-FirstCall/--Shireplc(LSE:SHP,NASDA...any,today,announcedthatithassubmittedaMAAtotheEuro...y,senzymereplacementtherapyindevelopment,forthetre...g,applicationforvelaglucerasealfathathasbeensubmit...nada. , Basedonaglobalsupplyshortageofthecurr...
(Date:11/24/2009)...lif.,Nov.24/PRNewswire-FirstCall/--GenomicHealth,I...omicHealth,sExecutiveChairman,willpresentatthe21st...yonTuesday,December1,2009at10:00a.m.ET. ,, Toac...entation,visittheInvestorRelationssectionofGenomic...m .Pleaseconnecttothewebsiteatleast15minutespriort...
(Date:11/24/2009)... Program Connects Customers with Partners Valid... DNA Genotek Products , O...k , a leading provider of products for biological ...today announced its new global partner program. Th...Genotek,s partner community and is designed to hel...
Breaking Biology Technology:AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Genomic Health to Present at Piper Jaffray Health Care Conference 2DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3
...quivalent to Humulin(R) R (recombinant human, i...all/ - SemBioSys Genetics Inc. (TSX:SBS), speciali... oils in plant seeds, today announced preliminary ...S-1000, a recombinant human insulin manufactured u...ted that SBS-1000 was bioequivalent to a recombina...
...9 Based on its recent analysis of the device biol...ech with the 2009 North American Frost & Sulli...s market is one of the most lucrative in the medic...ld has already experienced periods of breakthrough... , (Logo: http://www.newscom.com/cgi-bin/prnh/20...
...nomic, Inc. (OTC Bulletin Board: TBIO) today annou...year ended December 31, 2008. The Company,s financ...w. , , Fourth Quarter 2008 , The Company report...he fourth quarter of 2008 as compared to a net inc...quarter of 2007. , , Net sales from continuing op...
Other Biology Technology:SemBioSys Genetics Inc. Announces Clinical Results with Plant-Produced Insulin 2SemBioSys Genetics Inc. Announces Clinical Results with Plant-Produced Insulin 3SemBioSys Genetics Inc. Announces Clinical Results with Plant-Produced Insulin 4Frost & Sullivan Recognizes ApaTech's Leadership in Orthopedic Biologics 2Frost & Sullivan Recognizes ApaTech's Leadership in Orthopedic Biologics 3Frost & Sullivan Recognizes ApaTech's Leadership in Orthopedic Biologics 4Frost & Sullivan Recognizes ApaTech's Leadership in Orthopedic Biologics 5Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 2Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 3Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 4Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 5Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 6Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 7Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 8
(Date:11/23/2009)...rovides "incontrovertible evidence" that the volca...a about 73,000 years ago deforested much of centra...archers report. , The volcano ejected an estimat..., leaving a crater (now the world,s largest volcan...ters wide. Ash from the event has been found in In...
(Date:11/23/2009)...y by University of Alabama at Birmingham (UAB) res...xisting medical conditions (co-morbidity) do not e...an-Americans compared to Caucasians who also have ...3 in Cancer , a journal of the American Cancer So... and co-morbidity are independent predictors of po...
(Date:11/23/2009)...ent discoveries about the multiple health benefits...urpose nutrient, increased awareness of the huge n...research and even led to an appreciation of it as ...the health of your immune system to prevention of ... vitamin D is now seen as one of the most critical...
Breaking Biology News(10 mins):Supervolcano eruption -- in Sumatra -- deforested India 73,000 years ago 2Racial disparity in colon cancer survival not easily explained, UAB researchers say 2Multiple health concerns surface as winter, vitamin D deficiences arrive 2Multiple health concerns surface as winter, vitamin D deficiences arrive 3Reportable Food Registry Draft Guidance Published for Comment by FDA 49058 1Reportable Food Registry Draft Guidance Published for Comment by FDA 49058 2Gaiam and Discovery Communications Announce Exclusive Licensing Deal 49055 1Gaiam and Discovery Communications Announce Exclusive Licensing Deal 49055 2Gaiam and Discovery Communications Announce Exclusive Licensing Deal 49055 3Steelcase Inc Receives Five Best of NeoCon Awards and Best Overall Showroom for Nurture at NeoCon 2009 49052 1Steelcase Inc Receives Five Best of NeoCon Awards and Best Overall Showroom for Nurture at NeoCon 2009 49052 2Steelcase Inc Receives Five Best of NeoCon Awards and Best Overall Showroom for Nurture at NeoCon 2009 49052 3
... CLEVELAND The National Science Foundation (NSF)...University to prepare 24 high-achieving science an...e newly funded Robert Noyce Teacher Scholarship Pr...ase Western Reserve will seek to encourage science... and science teachers. The nearly $750,000 grant w...
... , For the first time, scientists have decoded the...isease - acute myelogenous leukemia - to its genet...encing Center and the Siteman Cancer Center at Was... sequenced the genome of the patient - a woman in ...he genome of her leukemia cells, to identify genet...
... In the study, the scientists screened known drug...e conventional reprogramming genes, which can have... new way to generate stem cells from fibroblasts, ...cessible from various tissues, including skin. , ...ition (Volume 3, Issue 5) of the journal Cell Ste...
Other Biology News:NSF grant to launch undergrads from Case Western Reserve into math and science teaching 2NSF grant to launch undergrads from Case Western Reserve into math and science teaching 3Washington University scientists first to sequence genome of cancer patient 2Washington University scientists first to sequence genome of cancer patient 3Washington University scientists first to sequence genome of cancer patient 4Washington University scientists first to sequence genome of cancer patient 5Scripps research scientists identify compounds for stem-cell production from adult cells 2Scripps research scientists identify compounds for stem-cell production from adult cells 3
pBICEP-CMV-3 Expression Vector from Sigma-Aldrich
... direct antibiotic-based selection system for reco...nds solely on colony survival, eliminating the nee...ensive process provides close to 100% accuracy in ...l platform for robot colony picking. This cloning ...
Eppendorf Thermomixer from Eppendorf North America
Mouse Anti-Human KCTD13 Polyclonal Antibody, Unconjugated from Abnova Corporation
Biology Products: